Abstracts tagged "Myocardial Infarction"

Abstract Number: 1615 • ACR Convergence 2022
Myocardial Infarction in Patients with Systemic Vasculitis and Population Controls: Characteristics and Overall Mortality
Pavlos Stamatis¹, Moman Mohammad², David Erlinge², Carl Turesson³, David Jayne⁴ and Aladdin Mohammad⁵, ¹Department of Clinical Sciences Lund, Rheumatology, Lund University, Sweden, Larissa, Larisa, Greece, ²Department of Clinical Sciences Lund, Cardiology, Lund University, Lund, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁴University of Cambridge, Cambridge, United Kingdom, ⁵Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden
Background/Purpose: The deleterious effect of inflammation combined with glucocorticoid treatment may increase the risk for atherosclerotic events. The aims of this study were to investigate…
Abstract Number: 1817 • ACR Convergence 2022
Acute Coronary Syndrome in Calcium Pyrophosphate Deposition Disease Patients: A Cross-sectional Study from the National Inpatient Sample
Konstantinos Parperis¹ and Bikash Bhattarai², ¹University of Cyprus Medical School, Nicosia, Cyprus, ²Valleywise Health, Phoenix, AZ
Background/Purpose: Calcium pyrophosphate deposition disease (CPPD) is a common crystal-induced arthritis characterized by the deposition of calcium pyrophosphate crystals in the articular tissues. Acute CPP…
Abstract Number: 1871 • ACR Convergence 2022
Hospitalization Outcomes for Acute Myocardial Infraction and Acute Heart Failure in Patients with Idiopathic Inflammatory Myopathies (IIM) from 2016-2019 National Inpatient Sample (NIS)
Zi Ying Li¹, Siyi Huang², Kevin Xi³, Deepan Dalal⁴ and Anthony Reginato⁵, ¹Roger Williams Medical Center, Providence, RI, ²UCSF Fresno, Fresno, CA, ³Brown University, Providence, ⁴Brown University School of Medicine, Providence, RI, ⁵Brown University, Providence, RI
Background/Purpose: Cardiovascular disease was encountered in 15% of hospital admission from 2016-2017 for patients with idiopathic inflammatory myopathies (IIM) based on the National Inpatient Sample…
Abstract Number: 1976 • ACR Convergence 2022
Outcomes of the First Episode of STEMI in Rheumatoid Arthritis from the National Inpatient Sample Database 2016-2019
Amar Suwal¹, Biraj Shrestha², Ibiyemi Oke² and Anthony Donato², ¹Reading Hospital, Tower Health, Reading, PA, ²reading hospital- tower health, Reading, PA
Background/Purpose: Patients with Rheumatoid arthritis (RA) have a higher burden of cardiovascular diseases (CVDs) than the general population, with most deaths resulting from myocardial infarctions.…
Abstract Number: 1915 • ACR Convergence 2021
Risk of Cardiovascular Outcomes with Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis
Brian Coburn¹, Michael George¹, Joshua Baker¹, Jesse Hsu², Qufei Wu¹, Lang Chen³, Fenglong Xie³, Huifeng Yun⁴ and Jeffrey Curtis⁵, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, Philadelphia, PA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama Birmingham, Birmingham, AL, ⁵Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Many guidelines recommend limiting glucocorticoids to short-term use in patients with rheumatoid arthritis (RA), but up to 40% of patients remain on glucocorticoids long-term.…
Abstract Number: 0446 • ACR Convergence 2021
Clinical Characteristics, Including History of Myocardial Infarction and Stroke, Among US PMO Women Initiating Treatment with Romosozumab and Other Anti-osteoporosis Therapies
Jay Lin¹, Carrie Nielson¹, Mary Oates¹, Cynthia Deignan² and Zhigang Yu¹, ¹Amgen Inc., Thousand Oaks, CA, ²Amgen, Inc., Agoura Hills, CA
Background/Purpose: This study is an ongoing USFDA post-marketing requirement (2020-2024) to assess the impact of boxed warning on romosozumab (romo) treatment and the feasibility of…
Abstract Number: 1099 • ACR Convergence 2021
Characteristics and Outcomes of Myocardial Infarction in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Gout and Osteoarthritis Patients Using the National Inpatient Sample Database from 2002-2018
Sonia Gupta¹, Vinay thallapally², Sarah Aurit², Rouhin sen³ and Joseph Nahas², ¹Creighton University School of Medicine, Omaha, NE, ²Creighton University, Omaha, NE, ³Colorado University Anschutz Medical Campus, Denver, CO
Background/Purpose: Patients with the autoimmune rheumatic disease have an increased risk of acute myocardial infarction (MI). Our study was designed to compare the prevalence, characteristics…
Abstract Number: 1833 • ACR Convergence 2021
Risk of Major Adverse Cardiovascular Events (MACE) with Biologic and Targeted Synthetic Antirheumatic Agents in Psoriatic Arthritis: A Systematic Review and Network Meta-analysis
Muhammad Ajmal¹, Jawad Bilal¹, Syed Arsalan Ahmed Naqvi², Irbaz Bin Riaz³, Zaina Shahid⁴, Kaneez Zahra Rubab Khakwani¹, Yi-Shao Liu⁵, Sandipan Bhattacharjee⁵, Roxanne Bogucka⁵, Noureen Asghar⁶ and Kent Kwoh¹, ¹University of Arizona, Tucson, AZ, ²Dow University of Health Sciences, Karachi, Pakistan, ³Mayo Clinic, Phoenix, AZ, ⁴Lehigh Valley Health Network, Allentown, PA, ⁵University of Texas at Austin, Austin, TX, ⁶Dow University of Health Sciences, Karachi
Background/Purpose: The efficacy of biologics and targeted synthetic disease modifying antirheumatic agents approved for treatment of psoriatic arthritis (PsA) is well documented, but cardiovascular safety…
Abstract Number: 0239 • ACR Convergence 2020
Adjudicated MACE and VTE in the Filgotinib RA Program: Integrated Analysis from Phase 2 and 3 Clinical Trials
Christina Charles-Schoeman¹, Sang-Cheol Bae², Arvind Chopra³, Stanley Cohen⁴, Jeffrey R Curtis⁵, Jacques-Eric Gottenberg⁶, Edward C Keystone⁷, Kunihiro Yamaoka⁸, Peter Nash⁹, J-Abraham Simon-Campos¹⁰, William Stohl¹¹, Michael Weinblatt¹², Rene Westhovens¹³, Jeff Siegel¹⁴, Iyabode Tiamiyu¹⁴, Lei Ye¹⁴, Deyuan Jiang¹⁴, Franziska Matzkies¹⁴, Angelika Jahreis¹⁴, John S. Sundy¹⁴ and Jon Giles¹⁵, ¹University of California, Los Angeles, Los Angeles, CA, ²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ³Center for Rheumatic Diseases, Pune, India, ⁴University of Texas Southwestern Medical School at Dallas, and Metroplex Clinical Research Center, Dallas, TX, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Strasbourg University Hospital, Strasbourg, France, ⁷Mount Sinai Hospital, Toronto, ON, Canada, ⁸Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan, ⁹School of Medicine Griffith University, Brisbane, Queensland, Australia, ¹⁰Köhler & Milstein Research, Mérida, Mexico, ¹¹University of Southern California Keck School of Medicine, Los Angeles, CA, ¹²Brigham and Women's Hospital, Boston, MA, ¹³University Hospitals Leuven, Belgium, Leuven, Belgium, ¹⁴Gilead Sciences, Inc., Foster City, CA, ¹⁵Columbia University, New York, NY
Background/Purpose: Filgotinib (FIL)—an oral, selective Janus kinase 1 inhibitor (JAKi)—improved RA signs and symptoms in three phase 3 trials. Despite the efficacy of FIL and…
Abstract Number: 1181 • ACR Convergence 2020
Gains in Cardiovascular Risk Knowledge Through Web Based Educational Intervention for Rheumatoid Arthritis Patients
Meenakshi Jolly¹, Courtney O'Brien¹, Aman Kugasia², Anna Gorfin³, Lauren Klebek³, Joshlean Fair³ and Joel Block¹, ¹Rush University, Chicago, IL, ²Arthritis Clinic of Cypress and Katy, PA, Katy, TX, ³Rush University, Chicago
Background/Purpose: Cardiovascular disease (CVD) is a leading cause of mortality in rheumatoid arthritis (RA). Ischemic heart disease in RA is often silent and precedes myocardial…
Abstract Number: 1390 • ACR Convergence 2020
Outcomes of Systemic Sclerosis Patients Who Were Primarily Admitted for Acute Myocardial Infarction from 2016 to 2017: Insights from the National Inpatient Sample
Atefeh Vafa¹, Omid Behnamfar² and Yih Chang Lin³, ¹University of South Florida, Tampa, FL, ²University of California San Diego, La Jolla, CA, ³University of South Florida, Morsani College of Medicine, Tampa, FL
Background/Purpose: Several systemic autoimmune rheumatic diseases have been shown to increase coronary artery disease (CAD) risk, notable rheumatoid arthritis and systemic lupus erythematosus. However, data…
Abstract Number: 1424 • ACR Convergence 2020
Outcomes of Hospitalizations for Acute Myocardial Infarction in Patients with ANCA Associated Vasculitis from the National Inpatient Sample
Atefeh Vafa¹, Marielys Figueroa Sierra¹, Omid Behnamfar², Hamayon Babary¹, Suraiya Afroz¹ and Yih Chang Lin³, ¹University of South Florida, Tampa, FL, ²University of California San Diego, La Jolla, CA, ³University of South Florida, Morsani College of Medicine, Tampa, FL
Background/Purpose: Several studies in the past have shown significantly increased risks of cardiovascular disease in patients with ANCA associated vasculitis (AAV). This association is thought…
Abstract Number: 1630 • ACR Convergence 2020
Long-term Safety of Tildrakizumab in Patients with Moderate to Severe Plaque Psoriasis: Incidence of Confirmed Major Adverse Cardiovascular Events Through 3 Years (148 Weeks) from Two Phase 3 Trials
Lars Iversen¹, Christopher EM Griffiths², Andrea Peserico³, Ignasi Pau-Charles⁴, Andrew Blauvelt⁵, Diamant Thaçi⁶ and Kristian Reich⁷, ¹Aarhus University Hospital, Aarhus, Denmark, ²The University of Manchester, Manchester, United Kingdom, ³DIMED University of Padua, Padua, Italy, ⁴Almirall R&D, Barcelona, Spain, ⁵Oregon Medical Research Center, Portland, OR, ⁶Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁷Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, and Skinflammation®, Hamburg, Germany
Background/Purpose: Tildrakizumab (TIL) is a high-affinity anti–interleukin-23p19 monoclonal antibody that is approved for the treatment of moderate to severe plaque psoriasis. The objective of this…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].